Pilar S SaÅ„chez-BlÃ¡zquez

List of Publications by Year
in descending order

95 papers	3,313 citations	101384 36 h-index	168136 53 g-index
97 all docs	97 docs citations	97 times ranked	2676 citing authors

#	Article	IF	Citations
1	Human HINT1 Mutant Proteins that Cause Axonal Motor Neuropathy Exhibit Anomalous Interactions with Partner Proteins. Molecular Neurobiology, 2021, 58, 1834-1845.	1.9	5
2	Calmodulin Supports TRPA1 Channel Association with Opioid Receptors and Glutamate NMDA Receptors in the Nervous Tissue. International Journal of Molecular Sciences, 2021, 22, 229.	1.8	9
3	The Ïƒ1 Receptor and the HINT1 Protein Control Î±2Î´1 Binding to Glutamate NMDA Receptors: Implications in Neuropathic Pain. Biomolecules, 2021, 11, 1681.	1.8	7
4	The ALS-Related Ïƒ1R E102Q Mutant Eludes Ligand Control and Exhibits Anomalous Response to Calcium. International Journal of Molecular Sciences, 2020, 21, 7339.	1.8	6
5	The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception. Molecular Brain, 2020, 13, 150.	1.3	13
6	Ligands Exert Biased Activity to Regulate Sigma 1 Receptor Interactions With Cationic TRPA1, TRPV1, and TRPM8 Channels. Frontiers in Pharmacology, 2019, 10, 634.	1.6	18
7	The Axonal Motor Neuropathy-Related HINT1 Protein Is a Zinc- and Calmodulin-Regulated Cysteine SUMO Protease. Antioxidants and Redox Signaling, 2019, 31, 503-520.	2.5	15
8	The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9. Molecular Neurobiology, 2018, 55, 4940-4951.	1.9	27
9	Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget, 2018, 9, 23373-23389.	0.8	39
10	Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. Molecular Brain, 2018, 11, 51.	1.3	80
11	Sigma 1 Receptor Antagonists Inhibit Manic-Like Behaviors in Two Congenital Strains of Mice. International Journal of Neuropsychopharmacology, 2018, 21, 938-948.	1.0	4
12	Increased PKC activity and altered GSK3Î²/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces. Scientific Reports, 2017, 7, 43468.	1.6	15
13	Schizophrenia and depression, two poles of endocannabinoid system deregulation. Translational Psychiatry, 2017, 7, 1291.	2.4	38
14	Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget, 2016, 7, 55840-55862.	0.8	66
15	The Ïƒ1 Receptor Engages the Redox-Regulated HINT1 Protein to Bring Opioid Analgesia Under NMDA Receptor Negative Control. Antioxidants and Redox Signaling, 2015, 22, 799-818.	2.5	71
16	HINT1 protein: A new therapeutic target to enhance opioid antinociception and block mechanical allodynia. Neuropharmacology, 2015, 89, 412-423.	2.0	37
17	Detecting Zinc Release Induced by Mu-Opioid Receptor Agonists in Brain Slices. Methods in Molecular Biology, 2015, 1230, 233-241.	0.4	2
18	The ON:OFF switch, Ïƒ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: Implications in neurological disorders. Oncotarget, 2015, 6, 35458-35477.	0.8	50

#	Article	IF	Citations
19	The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Frontiers in Pharmacology, 2014, 4, 169.	1.6	98
20	The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. International Journal of Neuropsychopharmacology, 2014, 17, 1943-1955.	1.0	45
21	HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity. Molecular Brain, 2013, 6, 42.	1.3	43
22	Cannabinoid Receptors Couple to NMDA Receptors to Reduce the Production of NO and the Mobilization of Zinc Induced by Glutamate. Antioxidants and Redox Signaling, 2013, 19, 1766-1782.	2.5	69
23	The plasticity of the association between mu-opioid receptor and glutamate ionotropic receptor N in opioid analgesic tolerance and neuropathic pain. European Journal of Pharmacology, 2013, 716, 94-105.	1.7	47
24	Chronic Pain Leads to Concomitant Noradrenergic Impairment and Mood Disorders. Biological Psychiatry, 2013, 73, 54-62.	0.7	149
25	Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. International Journal of Neuropsychopharmacology, 2013, 16, 151-162.	1.0	72
26	The Mu-Opioid Receptor and the NMDA Receptor Associate in PAG Neurons: Implications in Pain Control. Neuropsychopharmacology, 2012, 37, 338-349.	2.8	155
27	GPCRs Promote the Release of Zinc Ions Mediated by nNOS/NO and the Redox Transducer RGSZ2 Protein. Antioxidants and Redox Signaling, 2012, 17, 1163-1177.	2.5	40
28	The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain. Psychopharmacology, 2012, 221, 53-65.	1.5	40
29	Analgesic antidepressants promote the responsiveness of locus coeruleus neurons to noxious stimulation: Implications for neuropathic pain. Pain, 2012, 153, 1438-1449.	2.0	47
30	Direct Association of Mu-Opioid and NMDA Glutamate Receptors Supports their Cross-Regulation: Molecular Implications for Opioid Tolerance. Current Drug Abuse Reviews, 2012, 5, 199-226.	3.4	77
31	NO-released Zinc Supports the Simultaneous Binding of Raf-1 and PKCÎ³ Cysteine-Rich Domains to HINT1 Protein at the Mu-Opioid Receptor. Antioxidants and Redox Signaling, 2011, 14, 2413-2425.	2.5	31
32	RGSZ2 Binds to the Neural Nitric Oxide Synthase PDZ Domain to Regulate Mu-Opioid Receptor-Mediated Potentiation of theN-Methyl-D-Aspartate Receptor-Calmodulin-Dependent Protein Kinase II Pathway. Antioxidants and Redox Signaling, 2011, 15, 873-887.	2.5	30
33	The histidine triad nucleotide-binding protein 1 supports mu-opioid receptorâ€“glutamate NMDA receptor cross-regulation. Cellular and Molecular Life Sciences, 2011, 68, 2933-2949.	2.4	50
34	SUMO-SIM Interactions Regulate the Activity of RGSZ2 Proteins. PLoS ONE, 2011, 6, e28557.	1.1	13
35	Mu-Opioid Receptors Transiently Activate the Akt-nNOS Pathway to Produce Sustained Potentiation of PKC-Mediated NMDAR-CaMKII Signaling. PLoS ONE, 2010, 5, e11278.	1.1	57
36	Brain-specific GÎ±z interacts with Src tyrosine kinase to regulate Mu-opioid receptor-NMDAR signaling pathway. Cellular Signalling, 2009, 21, 1444-1454.	1.7	27

#	Article	IF	Citations
37	Gz Mediates the Long-Lasting Desensitization of Brain CB1 Receptors and is Essential for Cross-Tolerance with Morphine. Molecular Pain, 2009, 5, 1744-8069-5-11.	1.0	48
38	Opiates as Antidepressants. Current Pharmaceutical Design, 2009, 15, 1612-1622.	0.9	109
39	NMDAR-nNOS generated zinc recruits PKCÎ³ to the HINT1â€“RGS17 complex bound to the C terminus of Mu-opioid receptors. Cellular Signalling, 2008, 20, 1855-1864.	1.7	61
40	Calcium/calmodulin-dependent protein kinase II supports morphine antinociceptive tolerance by phosphorylation of glycosylated phosducin-like protein. Neuropharmacology, 2008, 54, 319-330.	2.0	23
41	Do Pharmacological Approaches that Prevent Opioid Tolerance Target Different Elements in the Same Regulatory Machinery?. Current Drug Abuse Reviews, 2008, 1, 222-238.	3.4	46
42	Sumoylated RGS-Rz Proteins Act as Scaffolds for Mu-Opioid Receptors and G-Protein Complexes in Mouse Brain. Neuropsychopharmacology, 2007, 32, 842-850.	2.8	49
43	Morphine Induces Endocytosis of Neuronal Î¼-opioid Receptors Through the Sustained Transfer of GÎ± Subunits to RGSZ2 Proteins. Molecular Pain, 2007, 3, 1744-8069-3-19.	1.0	40
44	RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons. Cellular Signalling, 2007, 19, 2558-2571.	1.7	33
45	Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS. Psychopharmacology, 2005, 180, 1-11.	1.5	39
46	Expression of Neural RGS-R7 and GÎ²5 Proteins in Response to Acute and Chronic Morphine. Neuropsychopharmacology, 2005, 30, 99-110.	2.8	39
47	Activation of Î¼-Opioid Receptors Transfers Control of GÎ± Subunits to the Regulator of G-protein Signaling RGS9-2. Journal of Biological Chemistry, 2005, 280, 8951-8960.	1.6	73
48	The RGSZ2 Protein Exists in a Complex with Î¼-Opioid Receptors and Regulates the Desensitizing Capacity of Gz Proteins. Neuropsychopharmacology, 2005, 30, 1632-1648.	2.8	69
49	RGS-Rz and RGS9-2 proteins control mu-opioid receptor desensitisation in CNS: the role of activated GÎ±z subunits. Neuropharmacology, 2005, 48, 134-150.	2.0	32
50	Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter. Neuropharmacology, 2005, 48, 853-868.	2.0	68
51	RGSZ1 and GAIP Regulate Î¼- but Not Î´-Opioid Receptors in Mouse CNS: Role in Tachyphylaxis and Acute Tolerance. Neuropsychopharmacology, 2004, 29, 1091-1104.	2.8	59
52	The GBeta5 subunit that associates with the R7 subfamily of RGS proteins regulates mu-opioid effects. Neuropharmacology, 2003, 45, 82-95.	2.0	37
53	Exogenous myristoylated-Gi2Î± subunits of GTP-binding proteins are mitogens following their internalization by astrocytes in culture. Molecular Brain Research, 2003, 110, 15-26.	2.5	3
54	The R7 Subfamily of RGS Proteins Assists Tachyphylaxis and Acute Tolerance at Î¼-Opioid Receptors. Neuropsychopharmacology, 2003, 28, 1983-1990.	2.8	66

#	Article	IF	Citations
55	Agonists determine the pattern of G-protein activation in Î¼-opioid receptor-mediated supraspinal analgesia. Brain Research Bulletin, 2001, 54, 229-235.	1.4	89
56	Administration of myr+-Gi2Î± subunits prevents acute tolerance (tachyphylaxis) to mu-opioid effects in mice. Neuropharmacology, 2001, 40, 560-569.	2.0	21
57	RGS9 proteins facilitate acute tolerance to mu-opioid effects. European Journal of Neuroscience, 2001, 13, 801-811.	1.2	80
58	Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. European Journal of Neuroscience, 2001, 13, 153-161.	1.2	22
59	[1] In vivo modulation of G proteins and opioid receptor function by antisense oligodeoxynucleotides. Methods in Enzymology, 2000, 314, 3-20.	0.4	27
60	Stimulation of Î¼- and Î´-opioid receptors enhances phosphoinositide metabolism in mouse spinal cord: evidence for subtypes of Î´-receptors. European Journal of Neuroscience, 1999, 11, 2059-2064.	1.2	17
61	Antibodies and antisense oligodeoxynucleotides to Î¼-opioid receptors, selectively block the effects of Î¼-opioid agonists on intestinal transit and permeability in mice. British Journal of Pharmacology, 1999, 127, 397-404.	2.7	17
62	Use of selective antagonists and antisense oligonucleotides to evaluate the mechanisms of BUBU antinociception. European Journal of Pharmacology, 1999, 383, 29-37.	1.7	7
63	Transport of CSF antibodies to GÎ± subunits across neural membranes requires binding to the target protein and protein kinase C activity. Molecular Brain Research, 1999, 65, 151-166.	2.5	8
64	Myr+-Gi2Î± and GoÎ± subunits restore the efficacy of opioids, clonidine and neurotensin giving rise to antinociception in G-protein knock-down mice. Neuropharmacology, 1999, 38, 1861-1873.	2.0	16
65	Local changes in GTP-binding protein immunoreactivities in human epileptogenic neocortex. Experimental Brain Research, 1998, 119, 153-158.	0.7	9
66	Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to Î¼ receptors. European Journal of Neuroscience, 1998, 10, 2557-2564.	1.2	37
67	The delta2-opioid receptor subtype stimulates phosphoinositide metabolism in mouse periaqueductal gray matter. Life Sciences, 1998, 62, PL253-PL258.	2.0	5
68	GX/Z Is Regulated by Î¼ But Not Î´ Opioid Receptors in the Stimulation of the Low KmGTPase Activity in Mouse Periaqueductal Grey Matter. European Journal of Neuroscience, 1997, 9, 1194-1200.	1.2	37
69	G-receptor antagonists increased the activating effect of mastoparan on low Km GTPase of mouse PAG. Cellular Signalling, 1995, 7, 151-155.	1.7	4
70	In vivo injection of antibodies directed against the cloned Î¼ opioid receptor blocked supraspinal analgesia induced by Î¼-agonists in mice. Life Sciences, 1995, 56, PL237-PL242.	2.0	9
71	Î¼-OPIOID RECEPTORS REGULATE PERTUSSIS TOXIN-INSENSITIVE Gx/z- AND Gq-TRANSDUCER PROTEINS IN THE PRODUCTION OF ANALGESIA IN THE MOUSE. Analgesia (Elmsford, N Y), 1995, 1, 429-432.	0.5	3
72	Mastoparan reduces the supraspinal analgesia mediated by Î¼/Î´-opioid receptors in mice. European Journal of Pharmacology, 1994, 258, 159-162.	1.7	5

#	Article	IF	Citations
73	Dissimilar efficacy of opioids to produce Î¼-mediated analgesia: Role of Gx/z and G12 transducer proteins. Life Sciences, 1994, 55, PL205-PL212.	2.0	14
74	Antibodies directed against Î± subunits of Gi, Gx/z, Go and GS transducer proteins reduced the morphine withdrawal syndrome in mice. Life Sciences, 1994, 55, PL445-PL450.	2.0	14
75	Antibodies raised against the N-terminal sequence of Î´ opioid receptors blocjed Î´-mediated supraspinal antinociception in mice. Life Sciences, 1994, 54, PL191-PL196.	2.0	7
76	GX/Z and Gi2 transducer proteins on Î¼/Î´ opioid-mediated supraspinal antinociception. Life Sciences, 1993, 53, PL381-PL386.	2.0	19
77	Î´-opioid supraspinal antinociception in mice is mediated by G13 transducer proteins. Life Sciences, 1993, 53, PL129-PL134.	2.0	10
78	Intracerebroventricular injection of antibodies directed against GsÎ± enhances the supraspinal antinociception induced by morphine, Î²-endorphin and clonidine in mice. Life Sciences, 1992, 51, PL237-PL242.	2.0	19
79	Further characterization of Î±N-acetyl Î²-endorphin-(1â€“31) regulatory activity, I: Effect on opioid- and Î±2-mediated supraspinal antinociception in mice. Life Sciences, 1992, 50, 2083-2097.	2.0	5
80	II. Î±N-acetyl human Î²-endorphin-(1â€“31) alleviates the morphine withdrawal syndrome in rodents: A comparative study with clonidine. Life Sciences, 1992, 50, 2099-2109.	2.0	9
81	Cholera toxin and pertussis toxin on opioid- and Î±2-mediated supraspinal analgesia in mice. Life Sciences, 1991, 48, 1721-1727.	2.0	46
82	Î±N-acetyl derivatives of Î²-endorphin-(1â€“31) and -(1â€“27) regulate the supraspinal antinociceptive activity of different opioids in mice. Life Sciences, 1991, 48, 1417-1427.	2.0	7
83	Intrathecal pertussis toxin attenuates the morphine withdrawal syndrome in normal but not in arthritic rats. Life Sciences, 1990, 46, 329-334.	2.0	13
84	Effect of intrathecal injection of pertussis toxin on substance P, norepinephrine and serotonin contents in various neural structures of arthritic rats. Life Sciences, 1990, 47, 1915-1923.	2.0	12
85	Evaluation of Î´ receptor mediation of supraspinal opioid analgesia by in vivo protection against the Î²-funaltrexamine antagonist effect. European Journal of Pharmacology, 1989, 159, 9-23.	1.7	29
86	Intracerebroventricular N-ethylmaleimide differentially reduces supraspinal opioid analgesia in mice. European Journal of Pharmacology, 1989, 166, 193-200.	1.7	11
87	Pertussis toxin differentially reduces the efficay of opioids to produce supraspinal analgesia in the mouse. European Journal of Pharmacology, 1988, 152, 357-361.	1.7	57
88	Neuropeptide Y is an inhibitor of neural function in the myenteric plexus of the guinea-pig ileum. Peptides, 1986, 7, 623-629.	1.2	35
89	Opioid activity of pro-enkephalin-derived peptides in mouse vas deferens and guinea pig ileum. Neuroscience Letters, 1985, 61, 267-271.	1.0	10
90	Opiate activity of peptides derived from the three opioid peptide families on the rat vas deferens. Neuropeptides, 1984, 5, 181-184.	0.9	9

#	Article	IF	Citations
91	Dynorphin1â€“13: interaction with other opiate ligand bindings in vitro. Brain Research, 1984, 302, 392-396.	1.1	21
92	Different modes of opiate interaction in rat vas deferens. Life Sciences, 1982, 31, 1683-1686.	2.0	0
93	Dynorphin(1â€“13), a long-lasting inhibitor of opiate receptor binding. Life Sciences, 1982, 31, 1789-1792.	2.0	37
94	Dynorphin(1â€“10)amide: A potent and selective analog of dynorphin(1â€“13). Life Sciences, 1982, 31, 1817-1820.	2.0	7
95	Impairment by apomorphine of one-trial passive avoidance learning in mice: The opposing roles of the dopamine and noradrenaline systems. Psychopharmacology, 1979, 61, 43-47.	1.5	23